Azure Synthetics Azure Synthetics Research peptides, clearly documented.
FR
Panier 0 Browse catalog
Sermorelin

Endocrine signaling research

Sermorelin

Peptide lyophilisé de recherche de signalisation endocrinienne pour l'examen des systèmes

Sermorelin is a GHRH 1-29 analog studied as a classic pituitary GH-axis research reference.

Plage de prix : 45.99 $ à 195.99 $
98.7%-99.3% Poudre lyophilisée 5 mg
Available documentation

Support can confirm any currently available COAs or batch documentation for this product.

Request available documents

Pour la recherche en laboratoire uniquement. Pas pour un usage humain ou vétérinaire. Non destiné à diagnostiquer, traiter, guérir, atténuer ou prévenir une maladie.

Stockage

Conserver scellé, froid, sec et protégé des variations de chaleur. Confirmez le stockage spécifique au produit à l'arrivée.

Notes d'expédition

Emballé pour la stabilité du transit avec une assistance aux commandes disponible pour les itinéraires par temps chaud.

Batch reference

Batch-linked certificate support is available through the documentation desk.

Contexte de recherche

Profil de recherche Sermorelin

Sermorelin is a 29-amino-acid analog corresponding to the active amino-terminal region of growth hormone-releasing hormone. It is used as a classic reference for pituitary GHRH-receptor signaling, stimulated GH release, endocrine responsiveness, and downstream IGF-1 measurements. Compared with CJC-1295 with DAC, sermorelin represents a shorter GHRH framework without the same half-life-extension design. Compared with ipamorelin and GHRP peptides, it acts through a different receptor pathway. Researchers generally select sermorelin when the study calls for a well-established GHRH 1-29 reference or a direct comparison of pituitary signaling across GHRH analogs and ghrelin-receptor secretagogues.

Mécanisme proposé

A synthetic GHRH(1-29) peptide that activates the pituitary GHRH receptor, increases cyclic AMP, and stimulates endogenous growth-hormone release from responsive somatotroph cells.

Effets rapportés dans les études

  • Human diagnostic and pharmacology studies reported acute GH release and used the response to evaluate pituitary reserve.
  • Downstream changes can include transient increases in GH and IGF-1-related markers when repeated exposure is studied.
  • Responses vary with age, pituitary function, endogenous somatostatin tone, timing, and prior exposure.

Critères de recherche courants

GHRH receptor signaling, cyclic AMP, peak and integrated GH, IGF-1, pituitary responsiveness, age-related response, pharmacokinetics, and comparison with longer-acting GHRH analogs.

Preuves et limites

The GHRH stimulation mechanism is well characterized, including historical human diagnostic use. This does not establish therapeutic equivalence of a catalog product.

External reading

Literature for context—not product proof.

Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.

Support and documentation

Questions about this product?

What documentation can I request before ordering?

Before ordering, contact support with the product name, selected format, andu2014if availableu2014an order or batch reference to request available batch-linked documentation.

What should I confirm before ordering?

Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.